Chronic Kidney Disease News

Sobi and Apellis Pharmaceuticals Inc. announced results from the phase 3 Valiant study showing the drug pegcetacoplan reduced proteinuria and stabilized eGFR compared to placebo in patients with glomerulopathy or glomerulonephritis.

Higher intake of total, animal and plant protein may be linked to lower mortality in older adults with mild or moderate chronic kidney disease, according to a cohort study.

The FDA has granted accelerated approval for Fabhalta to treat proteinuria in patients with primary IgA nephropathy, according to a press release.

Meta Pharmaceuticals has received FDA rare pediatric disease designation for its investigational new drug META-001-PH, according to a press release.

Many dialysis care providers in the United States may have limited knowledge about dementia, according to a web-based survey.

Higher nutritional risk may be associated with infection-related hospitalization but not cardiovascular disease-related hospitalization in patients on dialysis, according to results of a prospective study.

Diality has received FDA 510(k) clearance for its Moda-flx Hemodialysis System for acute and/or chronic renal failure, according to a press release.

Dapagliflozin may have a protective effect on kidney function in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease, data show.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

Patients who have diabetes at the time of kidney allograft loss may have a lower chance of survival compared without, according to .